

Special Issue

Cyclooxygenase (COX) and Lipoxygenase (LOX) in the Inflammogenesis of Cancer

Message from the Guest Editor

We are pleased to invite you to contribute your research article to a special issue entitled “Cyclooxygenase (COX) and Lipoxygenase (LOX) in the Inflammogenesis of Cancer”. The aim of the special issue is to update and underscore scientific evidence from molecular, animal, and human investigations suggesting that constitutive overexpression of either COX or LOX drives carcinogenesis, and reciprocally, that COX/LOX blockade has strong potential for cancer prevention and therapy. We welcome contributions that address the impact of COX/LOX overexpression on essential molecular features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, immunosuppression and metastasis); as well as epidemiologic and clinical investigations of anti-inflammatory agents and their potential role in the chemoprevention and therapy of cancer.

Guest Editor

Prof. Dr. Randall E. Harris

Colleges of Public Health & Medicine, The Ohio State University,
Columbus, OH, USA

Deadline for manuscript submissions

closed (15 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/110808

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)